The World Health Organization announced that it has halted the provision of the COVID-19 vaccine Covaxin, manufactured by India’s Bharat Biotech, through United Nations agencies to allow the producer to update facilities and resolve problems discovered during an inspection.
According to the statement, the WHO advised nations that had received the vaccine to take necessary steps but did not explain what those actions would be.
According to the WHO, it is verifying the suspension of supply of Covaxin manufactured by Bharat Biotech via UN procurement agencies and advising nations that received the vaccine to take necessary measures.
The WHO stated that the vaccine is effective and that there are no safety issues, but that the stoppage of export manufacturing will result in a disruption in Covaxin supplies.
It stated that the suspension is in reaction to the results of a WHO post-emergency use listing (EUL) inspection performed from March 14 to 22 and that the vaccine manufacturer has confirmed its commitment to cease Covaxin export manufacturing.
According to a statement issued today by Hyderabad-based Bharat Biotech, there is no influence on the efficacy and safety of the COVID-19 vaccine Covaxin.
The vaccine certificates supplied to the millions who have received Covaxin remain valid because there is no influence on the efficacy and safety of the vaccine, according to a statement made by Bharat Biotech, according to news agency ANI.